- TG Therapeutics (NASDAQ:TGTX) is up 10% premarket on light volume on the heels of its announcement of updated data from a Phase 2 clinical trial evaluating lead candidate ublituximab (TG-1101) in patients with relapsing forms of multiple sclerosis (MS). The results were presented at the ACTRIMS conference in San Diego, CA.
- The data, from 40 patients in five cohorts, showed 97.5% of subjects were relapse-free at week 24. Also, treatment with ublituximab completely eliminated all T1 Gd-enhancing lesions [brain lesions detected with contrast-enhanced MRI. Gadolinium (Gd) enhancement is a marker for blood-brain barrier breakdown and correlates (histologically) with the inflammatory phase of lesion development].
- Also, the one-hour infusion was well-tolerated and could potentially be a more favorable administration than alternatives.
- Results through week 52 are next up.
- Ublituximab is an anti-CD20 monoclonal antibody. It is currently being evaluated in two Phase 3s, ULTIMATE 1 and 2.
- Previously: TG's ublituximab shows treatment effect in mid-stage MS study; shares off 3% in biotech downdraft (Oct. 26, 2017)
- Now read: TG Therapeutics: Oncology Concern Looks Like Solid Bet In 2018
Original article